HC Wainwright Comments on Insmed’s Q2 Earnings (NASDAQ:INSM)

Insmed, Inc. (NASDAQ:INSM) – Stock analysts at HC Wainwright upped their Q2 2026 earnings per share estimates for Insmed in a report released on Friday, May 8th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will post earnings of ($0.95) per share for the quarter, up from their prior estimate of ($1.00). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Insmed’s current full-year earnings is ($2.41) per share. HC Wainwright also issued estimates for Insmed’s Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($3.21) EPS, FY2027 earnings at $0.57 EPS, FY2028 earnings at $2.85 EPS, FY2029 earnings at $5.48 EPS and FY2030 earnings at $8.37 EPS.

Several other research analysts have also recently commented on INSM. Wells Fargo & Company lowered their target price on Insmed from $177.00 to $160.00 and set an “overweight” rating for the company in a research note on Friday. Truist Financial set a $205.00 target price on Insmed in a report on Monday, January 12th. Roth Mkm reissued a “buy” rating and issued a $212.00 target price on shares of Insmed in a report on Friday, April 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a report on Tuesday, April 21st. Finally, Stifel Nicolaus boosted their target price on Insmed from $205.00 to $208.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $211.86.

Insmed Trading Up 2.5%

Shares of NASDAQ INSM opened at $103.89 on Tuesday. Insmed has a twelve month low of $64.85 and a twelve month high of $212.75. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. The stock has a fifty day simple moving average of $144.00 and a 200-day simple moving average of $164.56. The stock has a market capitalization of $22.52 billion, a PE ratio of -18.07 and a beta of 0.89.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The business had revenue of $305.96 million during the quarter, compared to analysts’ expectations of $300.81 million. During the same period in the previous year, the firm posted ($1.42) earnings per share. The company’s revenue was up 229.7% on a year-over-year basis.

Insider Activity at Insmed

In related news, COO Roger Adsett sold 88,060 shares of the business’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total value of $14,497,317.80. Following the transaction, the chief operating officer owned 106,810 shares in the company, valued at $17,584,130.30. The trade was a 45.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO William Lewis sold 10,699 shares of the business’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $143.97, for a total value of $1,540,335.03. Following the completion of the transaction, the chief executive officer owned 301,185 shares in the company, valued at $43,361,604.45. This trade represents a 3.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 161,193 shares of company stock worth $25,462,012 in the last quarter. Company insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Insmed

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. EULAV Asset Management acquired a new position in Insmed during the 3rd quarter worth approximately $12,961,000. Artisan Partners Limited Partnership grew its holdings in shares of Insmed by 49.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after acquiring an additional 1,623,342 shares during the period. Atika Capital Management LLC acquired a new stake in shares of Insmed in the 3rd quarter worth approximately $13,681,000. Nisa Investment Advisors LLC raised its stake in shares of Insmed by 374.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 10,466 shares of the biopharmaceutical company’s stock worth $1,507,000 after buying an additional 8,261 shares during the last quarter. Finally, Nordea Investment Management AB acquired a new position in shares of Insmed during the 4th quarter worth $3,492,000.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.